Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of RXC004 +/- Nivolumab in Advanced Malignancies
NCT03447470Phase 1Completed
- Sponsor
- Redx Pharma
- Start
- Mar 2019
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zamaporvint in solid tumor (advanced stage) (9 arms), sponsored by Redx Pharma. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2019; status: completed.
02
Drugs
zamaporvint
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03447470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03447470.